LONG-TERM EFFICACY AND SAFETY OF SPARSENTAN IN YOUNG PATIENTS WITH FSGS: 240-WEEK ANALYSIS OF THE DUET OPEN-LABEL EXTENSION (OLE)
Back
Abstract Number
WCN23-1184
Categories
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Chronic Kidney Disease Diagnosis, Classification and Progression
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
LONG-TERM EFFICACY AND SAFETY OF SPARSENTAN IN YOUNG PATIENTS WITH FSGS: 240-WEEK ANALYSIS OF THE DUET OPEN-LABEL EXTENSION (OLE)
Co-authors
Lieberman, K.(1)*;Paredes, A.(2);Srivastava, T.(3);Komers, R.(4);Murphy, E.(4);Trachtman, H.(5);
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)Hackensack University Medical Center, Pediatrics, Hackensack, United States;(2)Nicklaus Children’S Hospital, Nephrology, Miami, United States;(3)Children’S Mercy Hospital, Pediatric Nephrology, Kansas City, United States;(4)Travere Therapeutics- Inc., Nephrology, San Diego, United States;(5)University Of Michigan, Pediatrics, Ann Arbor, United States;
E-Poster
https://storage.unitedwebnetwork.com/files/1041/65e594f4ea3d29e46ede30cc1e3934ff.pdf
Audio File
if any